Press Releases

02/5/2014

Silicon Biosystems Wins New Product Innovation Award

Silicon Biosystems, S.p.A. announced that it has received the 2013 New Product Innovation Award for Global Single Cell Analysis Platform from Frost & Sullivan, a global growth consulting firm providing market research and analysis. This award, presented annually by Frost & Sullivan, recognizes a company that has created an innovative product with superior value-added features and benefits when benchmarked against competitors.

continue →

09/12/2013

Silicon Biosystems Acquired by Menarini Group

The Menarini Group, a privately held Italian pharmaceutical and diagnostics company, today announced it has acquired Silicon Biosystems, S.p.A. “The acquisition of Silicon Biosystems represents a unique opportunity for the Menarini Group to add an innovative high-tech company to our existing pharmaceutical and biotechnology programs in oncology,” said Lucia Aleotti, Chairman of the Menarini Group. “We are excited by the high potential of Silicon Biosystems’ technology, and the possibility we will have to dramatically impact patients’ lives.”

continue →

02/19/2013

Silicon Biosystems Receives Leonardo Start-Up Prize

Silicon Biosystems was presented the Leonardo Start-up Prize for 2012 by Italian Republic President Giorgio Napolitano. The Start-up Prize, new in 2012, was created by the Leonardo Committee to recognize young companies that have demonstrated innovation, international success, and have created social impact. 

continue →

05/31/2012

Silicon Biosystems Opens San Diego Laboratory to Support U.S. Expansion

Silicon Biosystems has opened laboratory facilities in San Diego on the La Jolla Torrey Pines mesa, amidst San Diego’s pharmaceutical and nonprofit biology research centers. The combined offices and laboratories will serve as a demonstration and training facility for Silicon Biosystems’ customers and will allow the company to offer rare cell sample processing as a fee-for-service.

continue →

04/1/2012

Silicon Biosystems to Present at J.P. Morgan Healthcare Conference

Silicon Biosystems, Inc., a provider of specialized molecular and cellular biology technology, announced today that the company will present at the 30th annual J.P. Morgan Healthcare Conference on January 11, 2012, at 8 a.m. at the Westin St. Francis Hotel in San Francisco. Senior management will present an overview of the company’s business and its proprietary platform used in clinical research of rare cells, such as circulating tumor cells, stem cells, and fetal cells.

continue →

11/30/2011

Silicon Biosystems Announces Sale to Baylor College of Medicine

Silicon Biosystems, Inc., a provider of specialized molecular and cellular biology technology, announced today that Baylor College of Medicine has agreed to purchase the company's DEPArray™ technology for use in research programs related to prenatal diagnostics and molecular oncology.


The decision to acquire the DEPArray™ technology at Baylor College of Medicine has been led by Dr. Arthur Beaudet, Chairman of the Department of Molecular and Human Genetics at Baylor.

application pdfSilicon Biosystems Announces Sale to Baylor College of Medicine

continue →

09/20/2011

Silicon Biosystems Announces Agreement with Fox Chase Cancer Center

Silicon Biosystems, Inc., announced today its entry with Fox Chase Cancer Center in Philadelphia, PA into an agreement for the company's DEPArray™ technology. Dr. Massimo Cristofanilli, Professor and Chairman of the Department of Medical Oncology, and his colleagues at Fox Chase Cancer Center will use DEPArray™ technology to advance understanding of micrometastatic disease and the genetic heterogeneity of cancers.

continue →

12/13/2010

Silicon Biosystems Forms U.S. Subsidiary

Silicon Biosystems, S.p.A., announced that it has formed a U.S. subsidiary operation, Silicon Biosystems, Inc., to be headquartered in San Diego, California. The newly formed business will focus on commercial operations and the development of the North American research and clinical diagnostics markets for the company’s DEPArray™ technology platform.

continue →
Ask Us a QuestionShare your DEPArray™ storySubscribe to newsletter